Transfusion‐associated graft‐versus‐host disease

Transfusion-Associated Graft-Versus-Host Disease with a Non-fatal Course

“…It is an under-diagnosed entity due to its rare occurrence and over lapping clinical manifestations with viral exanthem or a drug reaction [2]. The risk of TA-GVHD is much more common in a genetic homogenous population as in Japan with the risk of transfusion of blood from HLA-homozygous donors [3].…”

“…It has low incidence of 0.1-1 % in susceptible recipients with an extremely high mortality rate of 87-100 % [3]. The underlying pathogenesis of this dreaded condition is due to the donor T-cells that engraft, proliferate and mediate a cellular immune response against host tissues, resulting in damage to skin, liver, gastrointestinal tract and bone marrow [2]. The existence of an atypical TA-GVHD, which does not follow a fatal course and exhibit all the manifestations of GVHD, has been suggested.…”

“…Transfusion associated graft-versus-host disease (TA-GVHD) is a rare and a fatal complication of the transfusion of non-irradiated cellular blood components in susceptible recipients [2]. It has low incidence of 0.1-1 % in susceptible recipients with an extremely high mortality rate of 87-100 % [3].…”

Anti-CD3 Antibody Ameliorates Transfusion-Associated Graft-Versus-Host Disease in a Chemotherapy-Based Mouse Model With Busulfan and Fludarabine

“…The pathogenesis and mechanism of TA-GVHD are complex and likely similar to GVHD in patients who have undergone bone marrow transplantation. Infused donor lymphocytes can be activated , undergo proliferation and differentiation; these lymphocytes then attack GVHD-targeted organs and thus cause TA-GVHD (4) . The severity of TA-GHVD is correlated with the number and immune activity of T lymphocytes in blood components.…”

Nonlethal transfusion associated graft-versus-host disease in a severe combined immunodeficient patient

“…1,2 Usually, the fatal outcome of TAGVHD is explainable by the delay in diagnosis of the underlying immunodeficiency and therefore delayed institution of immunosuppressive therapy. Some case reports have demonstrated that TAGVHD in severe combined immunodeficient (SCID) patients can be treated successfully by allogeneic bone marrow transplantation.…”